Home » Stocks » HGEN

Humanigen Inc. (HGEN)

Stock Price: $16.10 USD 0.89 (5.85%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $16.18 +0.08 (0.50%) Mar 8, 7:50 PM
Market Cap 881.65M
Revenue (ttm) n/a
Net Income (ttm) -59.27M
Shares Out 43.49M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE 5.27
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $16.10
Previous Close $15.21
Change ($) 0.89
Change (%) 5.85%
Day's Open 16.09
Day's Range 15.55 - 16.80
Day's Volume 920,613
52-Week Range 7.75 - 24.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 17 hours ago

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Business Wire - 3 days ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 6 days ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.

Business Wire - 1 week ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

InvestorPlace - 2 weeks ago

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

Other stocks mentioned: AIM, CDMO, CYDY, FLGT, JAGX, PRTC
Business Wire - 3 weeks ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 1 month ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.

Business Wire - 1 month ago

BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they hav...

Other stocks mentioned: CDMO, CDMOP
Business Wire - 1 month ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...

Business Wire - 1 month ago

SAN DIEGO & BURLINGAME, Calif.--(BUSINESS WIRE)--Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, and ...

Market Watch - 1 month ago

Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 trea...

Other stocks mentioned: EBS
Seeking Alpha - 1 month ago

CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patien...

Other stocks mentioned: CYDY
Business Wire - 1 month ago

GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered i...

Other stocks mentioned: EBS
Business Wire - 1 month ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...

The Motley Fool - 1 month ago

The company announced an important change to one of its ongoing clinical trials.

Business Wire - 1 month ago

BURLINGAME, Calif. & CHICAGO--(BUSINESS WIRE)--Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 2 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 2 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 2 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 2 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies fo...

Business Wire - 2 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 3 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 3 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytok...

Zacks Investment Research - 4 months ago

Humanigen (HGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytok...

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

Seeking Alpha - 4 months ago

Humanigen starts dosing patients in Phase 3 COVID-19 vaccine trial. AbbVie reports positive topline data for AGN-190584 Phase 3 trial.

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

The Motley Fool - 5 months ago

The company's potential COVID-19 treatment seems promising.

Market Watch - 5 months ago

Shares of Humanigen Inc. HGEN, +24.06% shot up 26% in active morning trading Monday, extending gains after the biopharmaceutical company revealed an upbeat patient case report regarding use of...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), announced today that management will present a company overview and business update at the Oppenheimer Fall ...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine sto...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine stor...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 5 months ago

BURLINGAME, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine sto...

Business Wire - 5 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 6 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 6 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 6 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 6 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 7 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 7 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Business Wire - 7 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

About HGEN

Humanigen, a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Ph... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2013
CEO
Cameron Durrant
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
HGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 29.33, which is an increase of 82.17% from the latest price.

Price Target
$29.33
(82.17% upside)
Analyst Consensus: Buy